Previous Article | Next Article ![]()
Molecular and Cellular Biology, June 2005, p. 5253-5269, Vol. 25, No. 12
0270-7306/05/$08.00+0 doi:10.1128/MCB.25.12.5253-5269.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Steven L. Teitelbaum,4
John M. Papadimitriou,2
Reinhard Jahn,3
F. Patrick Ross,4* and
Ming H. Zheng1*
Units of Orthopaedics,1 Pathology, School of Surgery and Pathology, University of Western Australia, QEII Medical Centre, Perth, Western Australia, Australia,2 Department of Neurobiology, Max Planck Institute for Biophysical Chemistry, Göttingen 37077, Germany,3 Department of Pathology, Washington University School of Medicine, St. Louis, Missouri4
Received 6 December 2004/ Returned for modification 10 February 2005/ Accepted 4 March 2005
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Current models of membrane fusion are dominated by consideration of two types of proteins, namely small G proteins of the Rab family and soluble N-ethylmaleimide-sensitive attachment protein receptors (SNAREs) (31). Whereas SNAREs and their interacting proteins play crucial roles in lipid bilayer fusion, members of the Rab GTPase superfamily have emerged as key regulators of vesicular budding, motility, tethering and docking at all stages of exocytic and endocytic transport (57, 80). Over 60 Rabs exist in mammalian cells, each displaying differential expression and subcellular localization (56). Like other regulatory GTPases, Rabs act as molecular switches, cycling between GTP-bound (activated) and GDP-bound (inactive) conformations, enabling Rabs to recruit specific downstream effector protein complexes through which they elicit their biological functions (80).
The Rab3 proteins (Rab3A, -B, -C, -D) are a highly homologous subfamily of Rabs thought to play important roles in regulated exocytosis (32). Unlike most Rabs which are ubiquitously expressed, the different Rab3 members are restricted to cells types with high exocytic requirements (38, 45). Thus, Rab3A and C are expressed predominantly in neurons and neuroendocrine cells where they both localize to synaptic vesicles and secretory granules (22, 23). Rab3B is associated with tight junctions and secretory granules in epithelial cells and anterior pituitary glands (39, 78). In contrast, Rab3D is widely expressed in nonneuronal cells including adipocytes, exocrine glands and several haematopoietic cells, where it localizes to secretory granules and vesicles (4, 50, 58, 76). Accumulated evidence suggests that Rab3A and Rab3C act as negative regulators of exocytosis (25, 28), whereas Rab3B and Rab3D are positive modulators of the same process (5, 15, 39, 53, 60).
In the present study, we report the existence of Rab3D as the major isoform in mouse OCs and their precursors. Disruption of Rab3D function by either targeted inactivation or overexpression of a dominant-inhibitory Rab3D mutant impairs osteoclastic bone resorption in vivo and in vitro, respectively. Interestingly, this disruption correlates with morphological disturbances in the ruffled border membrane. Localization studies reveal that wild-type Rab3D associates with a subset of post-trans-Golgi network (post-TGN) vesicles reminiscent of secretory granules, while expression of dominant inhibitory Rab3DN135I inhibits the biogenesis of these compartments. Our data suggest that Rab3D is involved in regulating a previously uncharacterized post-TGN vesicle trafficking step that contributes to the maintenance of the OC ruffled border membrane and hence modulates the major function of the cell, namely bone resorption.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Generation and isolation of mouse osteoclasts.
OCs were generated in vitro using one of two culture systems. First, RAW 264.7 cells were cultured in T-25 culture flasks at 105 cells/flask, in six-well plates at 2 x 104 to 2.5 x 104 cells/well, in 96-well plates at 1 x 103 to 1.5 x 103 cells/well or on glass coverslips in 24-well plates at 104 cells/well in minimal essential medium alpha modification (
-MEM) containing recombinant glutathione S-transferase (GST)-RANK ligand (RANKL) (37, 79) at 50 to 100 ng/ml, with replacement of culture media every 2 to 3 days. OCs were evident after 5 to 7 days of culture. Cells were subsequently harvested and processed for total RNA extraction, immunoblotting, or immunocytochemistry. Alternatively, OCs were prepared from bone marrow macrophages (BMMs) by culture in
-MEM-10% fetal bovine serum (FBS) at a starting density of 1.5 x 105 cells per well in 48 well plates in the presence of 50 ng/ml human recombinant macrophage colony-stimulating factor (M-CSF; R&D Systems, Minneapolis, MN). After 3 days, cells were cultured for a further 4 days with GST-RANKL (100 ng/ml) and M-CSF (20 ng/ml). Cells were fixed and stained for the OC marker tartrate-resistant acid phosphatase (TRAP). OCs were scored as TRAP+ multinucleated (more than three nuclei) cells. Cells were subsequently harvested and processed for total RNA extraction, Western blot analysis, or immunofluorescence confocal microscopy.
Mature primary OCs were mechanically disaggregated from the long bones of 1- to 3-day-old mice essentially as described in detail by the methods of Boyde et al. (8) and Chambers et al. (13). Isolated cells were seeded onto either glass or dentin surfaces for 24 h before being fixed and processed for immunohistochemistry.
Tartrate-resistant acid phosphatase staining and bone resorption pit assay. Cells were stained for TRAP using a commercially available kit (387-A; Sigma), according to published methods (37). After staining, cells were rinsed with phosphate-buffered saline (PBS) and photographed and quantified under a light microscope. To study the ability of OCs to form resorption pits on dentin, RAW 264.7 cells and BMMs were seeded onto 150-µm-thick dentin slices and cultured for 9 days in the presence of either GST-RANKL alone or in combination with M-CSF. After 9 days, OCs were fixed and stained for TRAP activity. Dentin slices were then incubated in 2 M NaOH (2 h) and cells were removed by mechanical agitation and sonication. Resorption lacunae were visualized by scanning electron microscopy (SEM) (82) and resorptive parameters quantitated using Scion Image software (Scion Corporation, National Institutes of Health).
Reverse transcription (RT)-PCR cloning, Southern blotting, and sequence analysis. Mouse OC and brain cDNAs served as templates for the identification and isolation of Rab3 genes. Rab3 degenerative oligonucleotide primers were designed based on the conserved sequences of Rab3/Ras consensus amino acid sequences D1 (QNFDYM) and D2 (WDNAQV) (Genset Pacific Pty. Ltd., Lismore, Australia) (Table 1.). Total RNA was extracted from either mouse bone marrow-derived OCs or snap frozen adult mouse brain (C57 black) with RNAzol B (Tel Test, Friendswood, Texas) and mRNA was enriched using DYNABEADS in accordance to the manufacturer's instructions (DYNAL Inc., Lake Success, NY). cDNAs were synthesized from 2 µg of purified mRNA using 100 U of Moloney murine leukemia virus (M-MLV) reverse transcriptase (Promega Corp., Madison, WI) as described by the manufacturer's guidelines. PCR was performed using 1.0 U DyNAzyme polymerase (GeneWorks, Hindmarsh, Australia) with 0.4 mmol/liter of D1 and D2 primers, 125 µmol/liter of dinucleoside triphosphate (dNTP) in 10x PCR buffer (GeneWorks) and water in a total volume of 25 µl. Amplification was performed in a DNA thermal cycler (model 2400; Perkin Elmer, Boston, MA), using 94°C for 5 min, 94°C for 30 s, 50°C for 2 min, 72°C for 30 s, and final extension at 72°C for 10 min. PCR products were electrophoresed on a 1.5% agarose gel containing ethidium bromide (EtBr). A 342-bp amplimer corresponding to the predicted size of Rab3 proteins was gel purified (GeneWorks) and subcloned into a pCR2.1 TA cloning vector (Invitrogen, Mt. Waverly, Australia). A total of 20 clones were sequenced in both directions using an automated ABI 373 system and BLAST N (3) at the National Center for Biotechnology Information (NCBI) was used to screen for DNA and protein homologies via the world wide web.
|
-P32-labeled mouse Rab3 cDNA probe. Stringency washes were carried out twice with 2x SSC (1x SSC is 0.15 M NaCl plus 0.015 M sodium citrate), 0.1% sodium dodecyl sulfate (SDS) and once with 1x SSC, 0.1% SDS, and 0.2x SSC, 0.1% SDS. Finally membranes were exposed to X-Omat Blue XB-1 X-ray film (Amersham Life Sciences). Expression of mouse calcitonin receptor (CTR), Cathepsin K (Cath K), TRAP and Rab3 isoforms in RAW 264.7 and RANKL-differentiated OCs was evaluated by RT-PCR amplification using sets of gene specific primers based on published mouse sequences (Table 1.), using reverse transcription of total RNA isolated with RNAzol B with 100 U of M-MLV reverse transcriptase (Promega). Two microlitres of each cDNA was subjected to PCR using 1.0 U of DyNAzyme polymerase (GeneWorks) with 0.4 mmol/liter of murine CTR, Cath K, TRAP, Rab3A, Rab3B, Rab3C or Rab3D specific oligonucleotides (Genset Pacific Pty. Ltd), or 0.2 mmol/liter of acidic ribosomal phosphoprotein (36B4), 125 µmol/liter of dNTP in 10x PCR buffer (Geneworks) and water in a total reaction volume of 25 µl. Cycling parameters (30 cycles) were 94°C for 5 min, 94°C for 30 s, and annealing (45 s) of CTR at 62°C, of Cath K at 55°C, of TRAP at 55°C, of Rab3A at 62°C, of Rab3B at 56°C, of Rab3C at 58°C, of Rab3D at 55°C, and of 36B4 at 55°C; 72°C for 40 s; and a final extension step at 72°C for 10 min. Ten microliters of PCR products were separated on a 1.5% agarose gel containing EtBr and photographed.
Protein isolation and immunoblotting. To isolate protein from cultured OCs and RAW 264.7 cells, cells grown as monolayers were washed twice with ice-cold PBS and then lysed in triple lysis buffer containing 50 mM Tris HCl (pH 8), 150 mM NaCl, 0.02% sodium azide, 0.1% SDS, 100 µg/ml phenylmethylsulfonyl fluoride (PMSF), 1 µg/ml aprotinin, 1% Nonidet P40, 0.5% sodium deoxycholate, and a mixture of protease inhibitors (Sigma) at 4°C for 30 min. For total tissue protein extraction, snap-frozen tissues were ground mechanically by mortar and pestle before being lysed for in triple lysis buffer. Both cell and tissue lysates were cleared (12,000 x g, 10 min) and resulting postnuclear supernatants (PNS) were resolved by electrophoresis on a SDS-13% polyacrylamide gel and blotted onto a nitrocellulose membrane (Hybond ECL; Amersham Life Science), which was blocked in 5% skim milk in Tris-buffered saline-Tween 20 (TBS-T) for 40 min at room temperature. Enhanced yellow fluorescent protein (EYFP)-tagged proteins were detected using a primary rabbit polyclonal Living Colors A.v. Peptide antibody (anti-EGFP) (1:1,000) dilution (Clontech Laboratories Inc.) or primary rabbit polyclonal Rab3A (K-15) (1:300), Rab3D (1:5,000) or Rab3 (Cl42.1) (1:10,000) antibodies by incubation for 2 h at room temperature. Membranes were washed and incubated with a secondary HRP-conjugated anti-rabbit antibody (Sigma) at a 1:5,000 dilution for 1 h at room temperature. Development was performed using an enhanced chemiluminescent detection kit.
Triton X-114 phase extraction. Triton X-114 extraction of PNS was carried out as described by Bordier (1981) (7). Briefly, RAW 264.7 cell, OC and tissue PNS were adjusted to 1% Triton X-114 and incubated at 4°C for 30 min, layered over a sucrose cushion containing 6% sucrose, 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, and 0.06% Triton X-114, and incubated at 30°C for 5 min. Following centrifugation (300 x g for 3 min), the aqueous and detergent phases were collected and adjusted to equal volumes. The detergent phases were subjected to SDS-PAGE and immunoblotted for either EYFP or Rab3 isoforms as described above. Protein concentration was estimated by Bradford assay (Bio-Rad; Hercules, CA).
FISH. For in situ hybridization, PCR was used to generate a cDNA product that encoded the entire open reading frame of murine Rab3D. Amplimers were gel purified and cloned into the pCR2.1 vector using the Original TA Cloning Kit (Invitrogen). All clones were sequenced for the confirmation of gene orientation. Recombinant plasmids containing Rab3D inserts were linearized with BamHI and transcribed into digoxigenin (DIG)-labeled antisense riboprobes with T7 RNA polymerase, using a DIG RNA labeling kit (Boehringer Mannheim, Mannheim, Germany). Fluorescence in situ hybridization (FISH) was performed on OCs derived from neonatal mouse bone imprints, fixed with 4% paraformaldehyde in PBS, under high stringency conditions as described previously in detail (29). Detection of hybridization signal was performed using a fluorescent antibody enhancer kit (Boehringer Mannheim). Signals were assessed by confocal microscopy (Bio-Rad 1000; Bio-Rad).
Mice. Rab3D/ mice were generated as previously described (59). Littermate controls were used for all experiments. Only female mice were used for quantitative histomorphometric measurements. All animal work was approved by an institutional ethics committee in compliance with the National Health and Medical Research Council (Australia) guidelines.
Bone histology and histomorphometry. Twelve-week-old mice were used for the assessment of bone phenotype. Tibiae and femora were excised, cleared of soft tissue, fixed in 2% paraformaldehyde containing 0.5% glutaraldehyde in 0.1 M phosphate buffer overnight, and decalcified in 8% EDTA for at least 10 days. Consecutive histological sections up to 20 slices per bone were stained with either hematoxylin and eosin (H&E) or tartrate-resistant acid phosphotase histochemistry. Histomorphometric analysis of the secondary spongiosa was performed according to standard methods (54). Statistical differences between groups were assessed by Student's t test.
Transmission electron microscopy. Transmission electron microscopy was carried out essentially as described by the methods of McHugh et al. (44) but with minor modifications. Briefly, long bones from 4- to 5-day-old Rab3D/ and Rab3D+/+ littermates were dissected free of soft tissue and fixed with 2.5% glutaraldehyde, 4% paraformaldehyde in 0.01 M cacodylate buffer (pH 7.3) for at least 1 h at room temperature. After removal of the fixation solution, bones were decalcified for 5 days in 14% EDTA (pH 7.4) containing 0.1% glutaraldehyde. Subsequently, bones were washed, postfixed with 1% osmium tetroxide, dehydrated in ethanol, and embedded in Epon 812. Ultrathin sections were counterstained with lead citrate and examined with a Phillips CM 120 Biotwin transmission electron microscope (Phillips Inc, Eindhoven, The Netherlands).
Generation of stable RAW 264.7 cell lines expressing EYFP-Rab3D proteins.
An EYFP-Rab3D fusion protein construct was generated by excising a full length Rab3D insert from a pBTM 116 expression vector with EcoRI and SalI and sub-cloning the cDNA into the EcoRI and XhoI sites of the cytomegalovirus (CMV) driven mammalian expression vector pcDNA 3.1 (+) (Invitrogen). An approximately 700 bp region from the pEYFP vector was amplified using primers (+) 5'-ATGATTACGCCAAGCTTG-3' and () 5'-CGGAATTCCTTGTACAGC-3' to remove the TAA stop codon and insert a downstream EcoRI restriction site. The amplified fragment was subcloned into a pCR2.1 TA cloning vector as outlined in the manufacturer's instructions (Invitrogen). The EYFP-EcoRI insert was ligated into the BamHI and EcoRI sites of the pcDNA 3.1-Rab3D containing expression vector. An EYFP expression vector was subsequently generated by excising the EYFP-EcoRI cDNA insert from the pCR2.1 TA cloning vector with BamHI and EcoRI and subcloning it into the pcDNA 3.1 mammalian expression vector. A myc-tagged mouse Rab3DQ81L vector, kindly provided by Romano Regazzi (30), served as a template for the construction of a Rab3DQ81L active mutant using a forward primer Q81L (5'GGAATTCCGGATGGCATCCGCTAGTGA-3') in combination with oligonucleotides corresponding to the bovine growth hormone (BGH) polyadenylation sequence present in the vector (5'TAGAAGGCACACTCGAGG3'). A Rab3DN135I mutant was constructed by PCR using primers (GENSET Pacific PTY. Ltd) containing a single nucleotide exchange leading to an amino acid exchange (N135I) of the gene product. Forward primer (5'-ATCCTCGTGGGGATTAAGTGTGACCTG-3') and reverse primer (5'CAGGTCACACAC TTAATCCC CACGAGGAT-3') were used. A Rab3D
CXC mutant was established by deletion of the last 3 amino acids (CSC) using a reverse primer 5'-GCTCTAGAGCTAGCTGCTCGGCTGTGG-3' paired with the EYFP forward primer. Wild-type Rab3D fragments were excised from the pcDNA 3.1-EYFP vector and replaced by PCR fragments containing the various mutations. All constructs were sequenced to ensure fidelity of ligation and mutations.
To generate stable cell lines, expressing EYFP-Rab3D wild-type and mutant RAW 264.7 cells were transiently transfected by electroporation essentially as described previously (67) except that 20 µg of plasmid DNA was used for the transfection. After a 24-h recovery period, transfected cells were cultured in selection media containing 500 µg/ml geneticin (G418; Sigma) for 2 weeks. Colonies resistant to the antibiotic were selected, expanded and expression levels monitored using a combination of immunoblotting, FACS analysis, and confocal microscopy. For fluorescence-activated cell sorting (FACS), the cells were washed with PBS, trypsinized, pelleted, and resuspended in complete
-MEM (20% FBS) for sorting by a Facstar Plus cytometer (Becton Dickinson). Cell lines were routinely resorted to maintain the homogeneity of the populations.
GTP-binding assay.
Binding of [
-P32]GTP to proteins blotted on nitrocellulose membrane was carried out in accordance to the protocol of Bucci et al. (9). Briefly, whole cell lysates were subject to SDS-PAGE and transferred to nitrocellulose membranes, which were incubated in binding buffer (50 mM sodium phosphate, pH 7.5, 10 µM MgCl2, 2 mM dithiothreitol [DTT], 0.2% Tween 20, 4 µM ATP) for 30 min at room temperature, and then probed with 1 µCi/ml [
-P32]GTP (Amersham Life Sciences) in binding buffer for 2 h. After four 15 min washes with binding buffer, the blot was wrapped wet and exposed to film for 16 h and then subsequently stripped and processed for immunoblotting with rabbit polyclonal anti-Rab3D antibodies.
Fluorescence and time-lapse confocal microscopy. RAW 264.7 cells and OCs grown on glass coverslips were washed twice with PBS and fixed with 4% paraformaldehyde in PBS, pH 7.2, for 15 min. Subsequently, cells were incubated for 5 min in 0.2% Triton X-100 in PBS. Following permeabilization, cells were washed in PBS containing 2% bovine serum albumin (BSA) and labeled with primary antibodies for 45 min at room temperature. After extensive washing with PBS, primary antibodies were detected by goat anti-mouse, goat anti-rabbit, or sheep anti-chicken immunoglobulin G conjugated to either Alexa Fluor 488 or 546 (Molecular Probes Inc.) at a dilution of 1:1,000. After 30 min of incubation, cells were washed in PBS and mounted onto slides in low fade mounting medium (25% glycerol, 15% polyvinyl alcohol in Tris-PO4, pH 8.5). For the detection of F-actin microfilaments, cells were fixed and permeabilized as described above and incubated with rhodamine-conjugated phalloidin (1:100; Molecular Probes Inc.) for 2 h at room temperature. Cell nuclei were visualized by counterstaining with Hoechst dye (1:10,000; Molecular Probes Inc.). In some experiments, cells were incubated at 37°C with rhodamine-ß dextran (10,000 molecular weight; 50 µg/ml) for 4 h, Alexa Fluor 546-transferrin (20 µg/ml) for 30 min, or the fixable acidotropic probe Lysotracker Red DND-99 (100 nM) for 30 min (all from Molecular Probes Inc.) before being fixed and processed for microscopy. Fluorescence-based TRAP staining was performed according to the established methods of Filgueira and outlined in detail in reference 21.
Detection of fluorochromes was carried out by confocal laser scanning microscopy (CLSM) (MRC-1000; Bio-Rad), equipped with a krypton-argon laser or argon ion laser coupled to an epifluorescence Nikon Diaphot 300 inverted microscope. For the detection of immunofluorescent staining and EYFP-signal, both 60x oil immersion objective lens (Nikon; numerical aperture = 1.6) and 40x UV oil immersion objective lens (Nikon; numerical aperture = 1.2) were used. Forty serial optical sections (z = 0.1 µm) were acquired satisfying the Nyquist criteria for sampling. In some cases, individual OCs cultured on bone slices were assessed throughout the entire cell using serial optical sections (1-µm intervals). The serial optical sections (z-series) from each cell were collected for the construction of three-dimensional images.
For time-lapse microscopy, cells were grown on 8-well Coverglass chamber slides (Nalge, Nunc International) in complete medium buffered with HEPES (20 mM, pH 7.5) (Sigma H-3375) and mounted on a heated stage at 37°C. Serial images were taken at 5-s intervals for 10 min, and stacks were played as AVI files. Confocal sequences were collected as Bio-Rad PIC files and were converted to bitmaps for use in either Scion Imaging software (NIH) or Confocal Assistant 4.02. Images were collected with nonsaturating conditions set up by the use of an output look-up table (LUT).
| RESULTS |
|---|
|
|
|---|
-P32-labeled mouse Rab3 probe confirmed the identity of these products as Rab3 proteins. Cloning and sequence analysis revealed that the majority of clones (80%) encoded mouse Rab3D, as documented by their identity with the published sequence of mouse Rab3D (4). Similar results were obtained using OCs obtained by RANKL-differentiated RAW 264.7 cells. (Fig. 1C). Moreover, Rab3A and Rab3C message is weakly expressed and confined to the early stages of RANKL differentiation, while Rab3D expression is strong and constitutive throughout osteoclastogenesis.
|
Having established that Rab3D is the predominant Rab3 isoform expressed in OCs, we next confirmed its existence in authentic mouse OCs. To this end, primary OCs were isolated from the long bones of neonatal mice and probed for Rab3D using fluorescence in situ hybridization (FISH) and immunocytochemical methods. As shown in Fig. 1E, Rab3D mRNA is present throughout the cytoplasm of mature OCs, which also are positive for TRAP following double staining (unpublished data). RNase treatment prior to hybridization resulted in loss of signals in all cells, indicating the specificity of the probe for its target mRNA sequence. Rab3D protein is also detected throughout the cytosol in OCs when stained with Rab3D-specific antisera in both nonresorbing and highly resorbing OCs (Fig. 1F). Consistent with its membrane association, Rab3D (green) is localized to small punctate structures ranging in size from approximately 100 to 500 nm. These compartments are randomly distributed throughout the cytosolic compartment but appear concentrated within the juxtanuclear/Golgi region (nuclei in blue). Low levels of diffuse immunofluorescence are also detected in the cytosol, probably reflecting the unprenylated pool of Rab3D. Importantly, no appreciable staining is observed in the absence of Rab3D antisera or when OCs were treated with preimmune serum at equivalent dilution. In actively resorbing cells, identified by characteristic sealing zone formations (red), Rab3D-bearing vesicles show no obvious sign of polarized targeting to either the ruffled border or basolateral membrane domains. Thus, based on these data, we conclude that Rab3D, rather than Rab3A/B/C, is major Rab3 species expressed in mouse OCs.
Mice lacking Rab3D manifest a phenotype of osteopetrosis. The abundance of Rab3D in OCs suggests that this GTPase may play an important role in the physiology of these bone-resorbing polykaryons. To test this hypothesis, we examined the skeletal architecture of Rab3D-deficient mice. The animals are viable and fertile and do not display any overt phenotypic abnormalities (59). Histological examination of longitudinal sections of the distal metaphyseal regions of tibias reveals a higher trabecular bone volume in Rab3D/ mice compared to wild-type (WT) littermates (Fig. 2A). In particular, the spatial organization of the trabecular bone network is dense and irregular within the metaphysis of Rab3D/ animals as compared to their WT counterparts. Reflecting these morphological aberrations, histomorphometric parameters of decalcified tibial sections reveal that the volume of the trabecular bone (BV/TV) in the Rab3D knockout (KO) mice is increased more than two fold compared to WT mice (Fig. 2B). Consistent with this finding, both trabecular number (Tb.N) and thickness (Tb.Th) are increased by more than two-thirds in mice lacking Rab3D. In addition, trabecular separation (Tb.Sp) and total eroded surface (ES) are markedly lower in the bones of Rab3D/ animals. In contrast, there is little detectable difference in cortical bone thickness and epiphyseal architecture (unpublished data), suggesting no obvious effect of Rab3D on bone formation by osteoblasts in vivo. Together these histomorphometric results indicate that mice lacking Rab3D are osteosclerotic.
|
Since the ability of OCs to resorb bone is directly related to their ability to form and sustain a functional ruffled membrane we next used electron microscopy to examine the morphology of the ruffled border in Rab3D null and WT cells for potential anomalies (Fig. 3A). Strikingly, we find that the ruffled borders of OCs derived from Rab3D mutant mice are structurally abnormal. Whereas the ruffled borders of OCs from WT animals exhibit characteristic thin villous architecture, those in Rab3D/ OCs consistently comprise thick, blunted projections, not unlike those present in ß3 null OCs, which are also dysfunctional (44).
|
Disruption of osteoclastic bone resorption is dependent on the guanine nucleotide binding, but not prenylation, status of Rab3D.
To gain further insight into the mechanisms by which Rab3D regulates osteoclastic bone resorption, we used a mutagenic approach to interfere with GDP/GTP cycling and membrane targeting of Rab3D. Previous studies have shown that substitution of glutamine (Q) at position 81 with leucine (L) within the switch II GTP-binding domain of Rab3D results in a protein that is deficient in GTP hydrolysis and persists in the constitutively active GTP-bound conformation (15, 49, 63). One the other hand, substitution of asparagine (N) at position 135 for an isoleucine (I) in the G4 motif leads to a constitutively inactive protein that has reduced affinity for guanine nucleotides and serves as a dominant-inhibitory mutant (5, 15, 41). Therefore, we constructed constitutively active and inactive Rab3D mutants by site-directed PCR and stably expressed them as enhanced yellow fluorescent protein (EYFP) fusions in RAW 264.7 cells. In addition, we generated a geranylgeranylation mutant (EYFP-Rab3D
CXC) by truncation of the last three amino acids (CSC) of carboxyl terminal motif that is required for membrane attachment and targeting (14). As a control, a plasmid encoding EYFP alone was also expressed in parallel.
Clones resistant to antibiotic selection were isolated and expanded, and expression levels and transfection efficiencies were assessed by immunoblotting and flow cytometry (Fig. 4 and unpublished data). As shown in Fig. 4A EYFP-fusion chimeras were expressed at equivalent levels and moderately overexpressed compared to the endogenous Rab3D protein. To verify the biochemical characteristics of the fusion chimeras, we next evaluated their GTP-binding properties and geranylgeranylation status. As expected, WT, constitutively active and geranylgeranylation-deficient Rab3D fusion proteins efficiently recruit GTP. On the other hand, GTP-binding affinity is markedly enhanced in cells expressing constitutively active EYFP-Rab3DQ81L, a result that confirms its reduced GTPase activity (Fig. 4B). In comparison, no GTP-binding is detectable for the guanine-nucleotide binding-deficient mutant EYFP-Rab3N135I. Likewise, assessment of geranylgeranylation capacity by Triton X-114 phase partitioning revealed that all EYFP-tagged Rab3D fusion proteins, with the predicted exception of EYFP-Rab3D
CXC, partitioned almost exclusively into the detergent phase (Fig. 4C), indicating that they are efficiently geranylgeranylated when expressed in RAW 264.7 cells.
|
|
CXC, displayed similar resorptive ability and thus apparently does not interfere with endogenous Rab3D activity. These resorptive phenotypes are comparable to those of the EYFP alone (Fig. 5) and untransfected OC controls (unpublished data). In contrast, overexpression of dominant-negative EYFP-Rab3DN135I impaired osteoclastic bone resorption. Resorption pits of the N135I mutant are typically shallow with poorly demarcated borders. Reflecting these resorptive deficiencies, quantitative analysis reveals that both the number and size of resorptive lacunae is markedly diminished in OCs expressing dominant-negative EYFP-Rab3DN135I compared to all other transfected OCs (Fig. 6B). Furthermore, the percentage of total dentin surface resorbed is significantly lower in OCs transfected with EYFP-Rab3DN135I as compared to control cells. These differing resorptive capacities do not reflect differences in osteoclastogenic abilities of individual RAW 264.7 cell lines, because all stable EYFP-expressing clones were derived from the same parental RAW 264.7 (C4) sub-clone and subjected to equal rounds of passaging. Furthermore, we do not detect any significant differences in osteoclastogenic potential between the stable EYFP-expressing cell lines (Fig. 7A and B), nor do we observe any differences in their ability to activate osteoclastogenic signaling pathways such as RANKL-induced ERK activation (unpublished data). Consistent with our ex vivo observations, we also fail to observe any quantitative morphology differences in the ability to form F-actin rings, with more than 80% of all cells examined possessing well-defined sealing zones (Fig. 7A and C). Together, our findings indicate that formation of GTP-bound Rab3D, rather than GTP hydrolysis or geranylgeranylation, is the rate-limiting step regulating Rab3D function during osteoclastic bone resorption.
|
|
CXC prenylation-deficient mutant displays diffuse cytosolic fluorescence distribution that is comparable to that of EYFP alone. Similar distribution is also observed in transfected COS-1 and PC12 cells (unpublished data), although the size of the Rab3D-postive vesicles varied slightly between the cell types.
|
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
Previous studies employing immunoblotting have reported the existence of at least two Rab3 isoforms (Rab3A, Rab3B/C) in murine osteoclastic cells (1). In the present study, using an equivalent culture system, we identified all four Rab3 GTPases by degenerative RT-PCR. Moreover, using a combination of molecular, biochemical, and cell biological methods, we demonstrate that Rab3D, rather than Rab3A/B/C, is in fact the major Rab3 species expressed in mature OCs. The discrepancy between our data and those of Abu-Amer et al. probably results from differences in both culture systems and methods of detection. Thus, the variations in expression profiles might reflect the presence of contaminating bone cell species such as osteoblasts and chondrocytes which have been recently reported to express Rab3A, -B, and -C (6, 55). Furthermore, the 42.1 antibody used in studies of Abu-Amer et al. lacks the specificity to discriminate between Rab3A/B/C/D isoform. In contrast, we used an antibody that uniquely recognizes Rab3D.
The functions of many Rab proteins have been classically dissected by either genetic inactivation in mice and nematodes or the use of interfering mutants (2, 9, 25, 51, 64). Rab3D/ mice have been recently shown to have enlarged secretory granules in pancreatic acinar cells (59). Our finding that Rab3D/ mice exhibit an osteosclerotic phenotype extends the physiological importance of GTPases to bone remodeling. The fact that Rab3D/ mice undergo normal development and yet have a cumulative resorptive defect in vivo indicates that Rab3D is not important during development, but rather plays a role during adult life. This conclusion mimics the complex bone phenotypes of mice lacking the ß3-integrin, DAP12, Wasp, or NIK, each of which exhibits progressive osteosclerosis (11, 35, 44, 52). In the case of ß3, disruptions in OC activity are mirrored by deficiencies in ruffled border formation. Consistent with these earlier observations, ultrastructural analyses in the present study reveals that OCs lacking Rab3D possess similarly disorganized ruffled borders, suggesting that Rab3D may be an important modulator of the ruffled border formation and hence OC function.
Our in vitro mutagenesis studies provide further support for the concept that Rab3D plays a substantial role in bone resorption. Whereas overexpression of WT, constitutively active and prenylation deficient mutants of Rab3D do not exhibit any significant abnormalities, expression of the dominant-negative Rab3DN135I results in a profound impairment of osteoclastic bone resorption. These results are similar to those employing analogous Rab3D mutants in AtT20 cells, mast cells and pancreatic acini (5, 15, 19, 60). It may seem surprising that the resorptive deficiency in OCs harboring the N135I mutation is greater than to those from Rab3D KO animals. Thus far there has been no simple explanation for this discrepancy; however, it may reflect the differences in the systems employed (loss-of- function mutation verses gene ablation). In the case of Ras, it is now well established that, due to their reduced nucleotide-binding and thus higher tendency to attain a guanosine-nucleotide free state, dominant-inhibitory N-I mutants work by competing with normal endogenous Ras for binding to Ras-activation factors, i.e., Ras GEFs (27, 65, 77). This high affinity results in the formation of "dead-end" complexes, thereby preventing the activation of endogenous Ras by Ras GEF resulting in loss of function. The dominant-negative Rab mutants are thought to function similarly (10, 34, 43). Indeed, recent studies have shown that disruptions in pancreatic secretion are largely attributable to dominant-negative Rab3D mutants' ability to inhibit endogenous Rab3D activation, presumably via sequestering Rab3 GEFs (15, 16). Thus, considering the high homology of Rab3 isoforms, it is likely that sequestering Rab3 GEFs by Rab3DN135I not only disrupts endogenous Rab3D GDP/GTP exchange in OCs but inhibits the activation of other endogenous Rab3 proteins or Rab3-like molecules that may contribute to the resorptive process and thus account for the more pronounced resorptive defect. On the other hand, a single gene deletion in Rab3D-deficent might be compensated, at least partially, by redundancy. This is perhaps best exemplified by the recent phenotypic assessment of Rab3 quadruple KO mice which found that while the absence of all four Rab3 isoforms is lethal at birth, the expression of a single Rab3 allele is sufficient for survival (64).
Another interesting finding is the normal F-actin organization in Rab3D-deficent and mutant OCs, in light of the drastic impairments in ruffled border formation and bone resorption in vitro and in vivo. We interpret this observation to mean that a post-TGN vesicle trafficking step regulated by Rab3D is uncoupled from the cytoskeletal reorganization that accompanies OC attachment and formation of the sealing zone. This hypothesis is supported by two independent studies. First, the recent finding that while GGTOH treatment disrupts Rab activity and inhibits bone resorption in vitro, OCs still maintain their ability to form actin rings, implying that they are not coupled events (17). Second, studies by Saltel et al. (62) reported that OCs retained normal sealing zones following the blockade of Golgi trafficking.
An important step in unravelling the function of a membrane trafficking protein is to define its subcellular localization. Previous localization studies indicate that Rab3D is an established marker of secretory vesicles and granules. For example, Rab3D associates with zymogen granules in the exocrine pancreas (76), dense-core secretory granules in PC12 (41, 42) and AtT-20 cells (5), and ß-hexosaminidase-containing granules in mast cells (19, 60, 73). In the present study, we find that Rab3D associates with a unique subpopulation of post-TGN vesicles in OCs and their monocytic precursors. This conclusion is founded on several morphological observations. First, the co-localization between Rab3D and markers of the TGN is consistent with it being a late exocytic carrier vesicle. Second, Rab3D-bearing vesicles, although superficially comparable to endosomes and lysosomes, do not associate with a number of established early or late endocytic/lysosomal markers. Third, Rab3D-bearing vesicles are morphologically distinct from TRAP-containing transcytotic compartments (26, 75). Finally, time-lapse confocal microscopy reveals that Rab3D-bearing vesicles bud dynamically from the TGN and undergo homotypic fusions, an event analogous to immature granule-granule fusions as occur during secretory granule maturation (72). It appears that Rab3D functions as a molecular on/off switch to regulate the biogenesis and/or maturation of these compartments, as such events are blunted by inhibition of Rab3D activity. These findings are consistent with the hypothesis that Rab3D regulates the maintenance and maturation of secretory granules (59). Additional support for this position is provided by recent findings that show expression of dominant-inhibitory mutants of Rab3D impairs the biogenesis of secretory granules in neuroendocrine and endothelial cells (5, 36, 41).
In summary, our results raise the intriguing possibility that Rab3D functions to regulate a previously undocumented, physiologically relevant, rate-limiting post-TGN trafficking step that is required for the maintenance of the ruffled border during osteoclastic bone resorption. Future characterization of the content(s) and nature of these compartments together with the identification of the complement of effector molecules through which Rab3D exerts its regulatory function may uncover potential novel antiresorptive targets for the treatment of OC-mediated bone diseases.
| ACKNOWLEDGMENTS |
|---|
This research was supported by grants from the National Health and Medical Research Council of Australia and National Institutes of Health awarded to Ming-Hao Zheng (ID9736447), F. Patrick Ross (AR48812 and AR46852), and Steven L. Teitelbaum (AR32788, AR46523, and AR48853).
| FOOTNOTES |
|---|
Supplemental material for this article may be found at http://mcb.asm.org/. ![]()
Present address: Department of Stem Cell Biology, University of Groningen, University Hospital Groningen, A. Deusinglaan 1, NL-9713 AV Groningen, The Netherlands. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Alto, N. M., J. Soderling, and J. D. Scott. 2002. Rab32 is an A-kinase anchoring protein and participates in mitochondrial dynamics. J. Cell Biol. 158:659-668.
3. Altschul, S. F., T. L. Madden, A. A. Schaffer, J. Zhang, Z. Zhang, W. Miller, and D. J. Lipman. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25:3389-3402.
4. Baldini, G., T. Hohl, H. Y. Lin, and H. F. Lodish. 1992. Cloning of a Rab3 isotype predominantly expressed in adipocytes. Proc. Natl. Acad. Sci. USA 89:5049-5052.
5. Baldini, G., G. Wang, M. Weber, M. Zweyer, R. Bareggi, J. W. Witkin, and A. M. Martelli. 1998. Expression of Rab3D N135I inhibits regulated secretion of ACTH in AtT-20 cells. J. Cell Biol. 140:305-313.
6. Bhangu, P. S., P. G. Genever, G. J. Spencer, T. S. Grewal, and T. M. Skerry. 2001. Evidence for targeted vesicular glutamate exocytosis in osteoblasts. Bone 29:16-23.[Medline]
7. Bordier, C. 1981. Phase separation of integral membrane proteins in Triton X-114 solution. J. Biol. Chem. 256:1604-1607.
8. Boyde, A., N. N. Ali, and S. J. Jones. 1984. Resorption of dentine by isolated osteoclasts in vitro. Br. Dent. J. 156:216-220.[CrossRef][Medline]
9. Bucci, C., R. G. Parton, I. H. Mather, H. Stunnenberg, K. Simons, B. Hoflack, and M. Zerial. 1992. The small GTPase rab5 functions as a regulatory factor in the early endocytic pathway. Cell 70:715-728.[CrossRef][Medline]
10. Bucci, C., P. Thomsen, P. Nicoziani, J. McCarthy, and B. van Deurs. 2000. Rab7: a key to lysosome biogenesis. Mol. Biol. Cell 11:467-480.
11. Calle, Y., G. E. Jones, C. Jagger, K. Fuller, M. P. Blundell, J. Chow, T. Chambers, and A. J. Thrasher. 2004. WASp deficiency in mice results in failure to form osteoclast sealing zones and defects in bone resorption. Blood 103:3552-3561.
12. Cassady, A. I., A. Luchin, M. C. Ostrowski, and D. A. Hume. 2003. Regulation of the murine TRACP gene promoter. J. Bone Miner. Res. 18:1901-1904.[CrossRef]